Sol-Gel Technologies
SLGL

$0.7300

3.93%

Market Cap: $20.3M

About: Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.

Employees: 36

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 20 [Q1] → 20 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.38% less ownership

Funds ownership: 27.82% [Q1] → 26.44% (-1.38%) [Q2]

14% less capital invested

Capital invested by funds: $7.6M [Q1] → $6.56M (-$1.04M) [Q2]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

448%

upside

Avg. target

$4

448%

upside

High target

$4

448%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Raymond James

Elliot Wilbur

100% 1-year accuracy

1 / 1 met price target

448%upside

$4

Outperform

Downgraded

19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research

All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy

SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Zacks Investment Research

Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.

Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product generic to Zoryve® Cream(roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Technologies Announces Management Realignment

NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step down from his position as CEO and member of the Board.

Sol-Gel Technologies Announces Management Realignment

Zacks Investment Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million.

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that Padagis Israel Pharmaceuticals Ltd (“Padagis”), Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream (roflumilast cream, 0.3%), indicated for the treatment of plaque psoriasis in patients six years of age and older.

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

See News Rankings